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Background: Our previous study has shown that regardless of a relatively high amount of cholesterol, squid
homogenate lowers serum and hepatic cholesterol in animals. Since this work, we have developed a new method
to inhibit autolysis of squid proteins with sodium citrate. This study aims to investigate how squid homogenate
prepared with sodium citrate affects lipid metabolism in Sprague–Dawley rats at the molecular level.
Methods: We prepared squid homogenate with sodium citrate to inhibit autolysis of squid protein. In Experiment 1
(Exp. 1), rats were given a cholesterol-free control diet or a squid diet, with squid homogenate added at the level of
5% as dietary protein for 4 weeks. Blood, the liver and adipose tissue were taken after 6 hours fasting. Serum and
hepatic lipids and activities of enzymes related to lipid metabolism were measured. In Experiment 2 (Exp. 2), the
above-mentioned diets had cholesterol added at the level of 0.1% and given to rats. Lipid parameters, enzyme activities,
and gene expression of proteins involved in lipid metabolism in the liver and the small intestine were determined. In
addition, feces were collected for two days at the end of Exp. 2 to measure fecal excretion of steroids.
Results: In Exp.1, serum triglyceride and cholesterol were ~50% and ~20% lower, respectively, in the squid diet-fed rats
than in the control diet-fed animals while hepatic cholesterol was ~290% higher in the squid diet-fed rats. When
cholesterol was included into the diets (Exp. 2), serum lipids were significantly lower in the squid group while no
difference of hepatic lipid was seen between two groups. Activities of hepatic lipogenic enzymes were significantly
lower in rats on the squid diet while the enzyme responsible for fatty acid oxidation was not modified (Expt. 1 and 2).
Hepatic level of mRNA of microsomal triglyceride transfer protein was significantly lower in the squid group. In the
small intestine, the squid diet exhibited significantly lower gene expression of proteins involved in fatty acid transport
and cholesterol absorption. Fecal secretion of acidic steroids, but not neutral steroids, was higher in rats fed the squid
diet than in those fed the control diet.
Conclusion: These results imply that newly-developed squid homogenate has hypolipidemic potential primarily
through decreased absorption of bile acids in the small intestine and suppressed lipogenesis in the liver.
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Besides genetic factors, dietary factors have been known
to be associated with increased cholesterol in blood,
consequently modifying risk of coronary heart diseases
(CHD) [1]. Among them, the link between fish con-
sumption and CHD has been extensively studied [2-5].
There is little doubt that fish oil, especially omega-3 fatty
acids, is effective in improving lipid profile and subse-
quently reducing risk of CHD [6]. Studies have sug-
gested that fish oil displays a wide spectrum of biological
activities, including hypotriglyceridemic, antiinflamma-
tory and antithrombotic activities [7]. However, the role
of other constituents in fish such as protein in develop-
ment of various diseases has been less conclusive com-
pared to those of fish oil, although fish proteins appear
to be less hyperlipidemic than animal proteins [8-11].
Some shellfish such as crab, squid and shrimp have a
relatively high content of cholesterol [12], which often
discourages subjects with hypercholesterolemia from
eating them. However, a few studies have been carried
out to see how shellfish affect lipid metabolism [12,13];
some shellfish favorably affect cholesterol metabolism,
increasing HDL2 cholesterol or HDL2-/HDL3-cholesterol
ratio. Squid contains a relatively low amount of fat
(4.3%) and a high amount of cholesterol (~100 mg/100 g
dry matter) [14]. Nevertheless, we previously reported
that in mice and rats, squid reduced serum and liver
lipids in the presence and absence of dietary cholesterol
[14,15]. The fact that defatted squid also suppressed
serum lipids in rats is indicative of hypolipidemic action
of squid proteins since defatted squid contains >85%
protein as dry matter [15]. When caught in the sea,
squid proteins are easily degraded because of autolysis.
Thus, elastic thermal gel of squid could not be pro-
duced, and commercial value of squid could be lost forTable 1 Effects of the diets on body weight, food intake and
Con
Body weight
Final (g) 396 ±
Gain (g/day) 4.40 ±
Food intake (g/day) 23.5 ±
Tissue weight
Liver weight (g/100 g BW) 4.19 ±





Brown adipose tissue weight (g/100 g BW) 0.142 ±
Data are mean ± SE (n = 6).
*Significantly different from the control group at p < 0.05.fish cake processing. We have tried to diminish autolysis
and found that sodium citrate inhibits autolysis of squid
mantle muscle [16]. Therefore, squid homogenate pre-
pared with sodium citrate could contain more intact pro-
teins compared to squid homogenate used in the previous
study [15]. The aim of this study was to see if newly-
developed squid homogenate lowers lipid levels in blood
and the liver, and to determine how squid homogenate
modifies lipid metabolism at the molecular level.
We here show that squid homogenate reduces serum
lipids and hepatic lipogenic enzyme activity, alters gene
expression of lipid-related proteins, and modifies lipid
metabolism at the molecular level in rats.
Results
Experiment 1
As shown in Table 1, body weight gain and liver weight
were not affected by the diets while the squid diet animals
had significantly lower food intake and perirenal adipose
tissue weight compared to the control diet animals. Serum
levels of triglyceride, cholesterol and phospholipid were
significantly lower in rats fed the squid diet compared
to those fed the control diet (Table 2); triglyceride level
was ~50% lower in rats on the squid diet. On the other
hand, hepatic cholesterol level was significantly higher
in rats on the squid diet when compared to those on the
control diet. Activities of enzymes involved in lipid me-
tabolism are described in Table 3. Feeding the squid diet
showed a trend toward lower activity of lipogenic enzymes
with significantly lower malic enzyme (ME), glucose-6-
phosphate dehydrogenase (G6PDH) and phosphatidate
phosphohydrolase (PAP). In contrast, carnitine palmitoyl-
transferase (CPT), the rate-limiting enzyme of fatty acid
oxidation, in the liver and brown adipose tissue was not
altered by the diets.tissue weight (Exp.1)
trol Squid
14 401 ± 8
0.31 4.80 ± 0.10
0.6 20.4 ± 0.6*
0.15 3.93 ± 0.08
0.20 0.89 ± 0.06*
0.14 1.59 ± 0.16
0.06 0.89 ± 0.06
0.30 3.37 ± 0.27
0.013 0.121 ± 0.009
Table 2 Effects of the diets on the concentrations of
serum hepatic lipids (Exp.1)
Control Squid
Serum
Triglyceride (mg/dL) 205 ± 12 106 ± 10*
Phospholipid (mg/dL) 171 ± 10 100 ± 1*
Cholesrerol (mg/dL) 102 ± 5 81.3 ± 1.6*
Liver
Triglyceride (mg/g) 29.3 ± 3.2 45.3 ± 5.3
Phospholipid (mg/g) 14.7 ± 0.5 14.4 ± 0.2
Cholesrerol (mg/g) 3.61 ± 0.24 10.5 ± 1.2*
Data are mean ± SE (n = 6).
*Significantly different from the control group at p < 0.05.
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To make the level of dietary cholesterol in the control
diet equivalent to that in the squid diet, cholesterol was
added to diets at the level of 0.1%. As shown in Table 4,
no effect of the diets was seen on body weight gain,
food intake, liver weight and adipose tissue weight.
Serum levels of triglyceride, phospholipid and choles-
terol were ~45%, ~35% and ~17% lower, respectively, in
the squid group compared to the control group (Table 5).
However, there was no significant difference in hepatic
concentrations of triglyceride, cholesterol and phospho-
lipid between two diets. The squid diet markedly affected
hepatic lipogenic enzyme activities (Table 6); animals dis-
played significantly lower enzyme activities of fatty acid
synthase (FAS) and PAP compared to the control diet.
However, the diets did not change CPT activity. As shown
in Table 7, fecal weight and fecal excretion of fatty acid
were not influenced by the diets whereas fecal excretion
of acidic steroids was significantly higher in the squid
group than the control group with no change in neutral
steroids. Figure 1 illustrates expression of genes involved
in hepatic lipid metabolism. The expression of 3-hydroxy-
3-methylglutaryl-coenzyme A reductase (HMG-CoAR),
essential for cholesterol synthesis, was non-significantlyTable 3 Effects of the diets on activities of hepatic enzymes i
Lipogenic enzyme (nmol/min/mg protein)




Fatty acid-oxidizing enzyme (nmol/min/mg protein)
Carnintine palmitoyltransferase
In the liver 2.88
In brown adipose tissue 7.52
*Significantly different from the control group at p < 0.05.down-regulated by the squid diet (p =0.1) while that of
CYP7A1, the rate-limiting enzyme in bile acid synthesis,
was up-regulated (p =0.08). Although fecal excretion of
bile acid, a ligand for farnesoid X receptor (FXR), was
significantly enhanced by the squid diet, mRNA of
hepatic FXR was not changed by the squid diet. Gene
expression of enzyme responsible for fatty acid synthesis,
FAS, was lower in the squid group than in the control
group without a significant difference (p =0.17). The squid
diet showed a significantly lower hepatic expression of
microsomal triglyceride transfer protein (MTP), essential
for very low density lipoprotein (VLDL) assembly/secre-
tion (p <0.05). As shown in Figure 2, gene expression of
jejunum Niemann- Pick C1-like 1 (NPC1L1), a critical
mediator of intestinal dietary cholesterol absorption, was
significantly lower in rats on the squid diet compared to
those on the control diet (p <0.05), but the diets did not
significantly alter acyl-coenzyme A:cholesterol acyltrans-
ferase 2 (ACAT2), the rate-limiting enzyme in intestinal
cholesterol trafficking. In addition, mRNA of fatty acid
translocase (CD 36), fatty acid transporter, in the jejunum
was significantly lower in rats fed the squid diet compared
to those fed the control diet (p <0.05). Gene expression of
ileal bile acid binding protein (IBABP) (p =0.09), bile acid
transporter, was lower in the squid group without a signifi-
cant difference (Figure 2).
Discussion
It has long been known that dietary protein affects chol-
esterol level in blood; animal proteins such as casein are
hypercholesterolemic while vegetable proteins such as
soybean are hypocholesterolemic [8]. Studies have previ-
ously suggested that hypocholesterolemic action of soy
protein is primarily due to peptides [17,18]. It’s been
reported that peptides from soybean reduce solubility of
cholesterol in micelle [18]. Some peptides appeared to
bind to bile acids in the small intestine, thereby decreas-
ing bile acids returning to the liver [19,20]. Cholesterol
is then converted to bile acids to compensate for thenvolved in lipid metabolism (Exp.1)
Control Squid
± 1.73 4.12 ± 1.58
± 2.9 8.9 ± 1.7*
± 3.6 11.6 ± 2.7*
± 9.04 22.3 ± 2.85*
± 0.33 2.25 ± 0.28
± 0.85 8.01 ± 0.79
Table 4 Effects of the diets on body weight, food intake and tissue weight (Exp.2)
Control Squid
Body weight
Final (g) 351 ± 17 352 ± 8
Gain (g/day) 7.49 ± 0.40 7.52 ± 0.27
Food intake (g/day) 20.5 ± 0.8 21.1 ± 0.9
Tissue weight
Liver weight (g/100 g BW) 4.29 ± 0.08 4.00 ± 0.14
White adipose tissue weight (g/100 g BW)
Perirenal 1.45 ± 0.16 1.29 ± 0.27
Epididymal 1.08 ± 0.06 1.01 ± 0.15
Mesenteric 1.06 ± 0.08 0.923 ± 0.161
Total 3.58 ± 0.28 3.22 ± 0.56
Brown adipose tissue weight (g/100 g BW) 0.153 ± 0.011 0.156 ± 0.009
Data are mean ± SE (n = 6-7).
Nagata et al. Lipids in Health and Disease 2014, 13:165 Page 4 of 10
http://www.lipidworld.com/content/13/1/165decreased bile acid pool, lowering cholesterol level in
serum and/or the liver. Many studies have since tried to
pinpoint peptides responsible for cholesterol-lowering
action [21-23]. Studies investigating dietary proteins
and peptides with hypocholesterolemic action have used
mainly vegetable proteins such as rice and soybean
[20,22,24]. On the other hand, a few studies have been
explored using shellfish [12-15]. Squid homogenate pre-
pared with sodium citrate in the current study retained
heavy chain myosin more intact as compared to that
prepared by simply mincing squid [25]. Seventy five per-
cent of dietary protein (casein) was replaced with squid
homogenate in the previous study [15] while a quarter
of it was substituted with sodium citrate-treated squid
homogenate in the current study. Therefore, although we
did not directly compare effects of sodium citrate-treated
squid homogenate on lipid parameters with those of squid
homogenate previously prepared by Tanaka et al. [15], the
present study suggests that squid homogenate prepared by
the new method may have more hypolipidemic potential
than that previously prepared. This similar hypolipidemicTable 5 Effects of the diets on the concentrations of
serum and hepatic lipids (Exp.2)
Control Squid
Serum
Triglyceride (mg/dL) 177 ± 24 97.7 ± 8.7*
Phospholipid (mg/dL) 153 ± 9 100 ± 8*
Cholesrerol (mg/dL) 78.3 ± 2.9 65.3 ± 1.3*
Liver
Triglyceride (mg/g) 75.4 ± 4.1 70.4 ± 9.8
Phospholipid (mg/g) 17.0 ± 0.5 17.3 ± 0.2
Cholesrerol (mg/g) 4.99 ± 0.39 4.15 ± 0.35
Data are mean ± SE (n = 6-7).
*Significantly different from the control group at p < 0.05.effect despite using a smaller amount of squid hom-
ogenate may be that intact proteins simply bind to bile
acids more than autolyzed proteins. Alternatively, pep-
tides responsible for bile acid binding may be partly
decomposed during homogenate preparation in the pre-
vious study. Tanaka et al. [15] have shown that defatted
squid lowers serum and hepatic cholesterol and hepatic
triglyceride accompanied with enhanced bile acid secre-
tion into feces in rats, indicating that protein, but not
lipids, is responsible for lipid-lowering action of squid.
However, in a mouse study, defatted squid-fed mice had
higher levels of serum lipids compared to the control
diet-fed animals [14]. The discrepancy is probably due
to species difference and different dietary composition;
the mouse study used lard as fat source and sucrose as
carbohydrate source while soybean oil and a mixture of
cornstarch and sucrose were added in our rat study.
Studies using various types of fish protein did not clearly
show changes in serum triglyceride in rats although low-
ered cholesterol was seen in the liver [10,11]. Rice and pea
proteins had hypotriglyceridemic action in rats as well
as hypocholesterolemic action [26,27] while another
study with vegetable proteins showed hypocholesterole-
mic action, but not hypotriglyceridemic action [28]. It
thus seems likely that dietary proteins derived from dif-
ferent sources modify lipid metabolism differently.
Then, to clarify mechanisms responsible for triglyceride-
lowering action of squid homogenate in more detail, we
measured activities of hepatic enzymes involved in lipid
metabolism. Whether or not cholesterol was in the control
diet, animals fed the squid diet exhibited a lower activity of
enzymes synthesizing fatty acids including FAS, ME and
G6PDH (Tables 3 and 6). This corroborates results from
the study with defatted squid in which activities of FAS,
ME and G6PDH were reduced [15]. On the other hand,
CPT, the rate-limiting enzyme in fatty acid oxidation, was
Table 6 Effects of the diets on activities of hepatic enzymes involved in lipid metabolism (Exp.2)
Control Squid
Lipogenic enzyme (nmol/min/mg protein)
Fatty acid synthase 4.67 ± 0.99 2.40 ± 0.58*
Malic enzyme 15.7 ± 2.7 9.70 ± 1.03
Glucose-6-phosphate dehydrogenase 8.51 ± 1.43 4.12 ± 0.50
Phosphatidate phosphohydrolase 5.91 ± 0.32 4.82 ± 0.20*
Fatty acid-oxidizing enzyme (nmol/min/mg protein)
Carnintine palmitoyltransferase
In the liver 2.12 ± 0.42 2.36 ± 0.58
In brown adipose tissue 5.95 ± 0.86 4.55 ± 1.16
Data are mean ± SE (n = 6-7).
*Significantly different from the control group at p < 0.05.
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ceride to be at least in part due to suppression of fatty acid
synthesis, but not enhancement of fatty acid oxidation.
Furthermore, gene expression of MTP, responsible for
VLDL assembly/secretion, was significantly lower in the
squid group, suggesting that squid homogenate may alter
hepatic secretion of VLDL triglyceride. Collectively, these
results imply that squid homogenate modulates synthesis
and secretion of triglyceride in the liver at the molecular
level. Since activities of lipoprotein lipase (LPL) and hepatic
lipase (HL) were enhanced by rice protein [26], dietary
protein may stimulate clearance of triglyceride from the
circulation. It is therefore of interest to see how squid
homogenate affects secretion of triglyceride from the
liver, clearance of triglyceride from the circulation, and
uptake of triglyceride in peripheral tissues such as
muscle in further studies. Hepatic triglyceride levels in
Exp. 2 were higher than those in Exp. 1 in the present
study. Although adding cholesterol diets might have
increased hepatic triglyceride as observed by Tanaka
et al. [15], the precise mechanism is currently unclear.
However, since there was no difference of hepatic trigly-
ceride between the control group and the squid group,
and since weight of the liver and adipose tissue tended
to be lower in squid-fed rats, the levels of hepatic trigly-
ceride in the squid group may not be detrimental.Table 7 Effects of the diets on fecal fatty acid and steroid
excretion (Exp.2)
Control Squid
Dry feces weight (g/2 day) 4.27 ± 0.33 4.41 ± 0.26
Fatty acid (mg/2 day) 69.4 ± 8.3 61.2 ± 3.3
Neutral steroids (mg/2 day) 8.27 ± 0.83 8.50 ± 0.76
Acidic steroids (mg/2 day) 24.4 ± 2.3 33.7 ± 4.3*
Total steroids (mg/2 day) 31.8 ± 2.1 42.2 ± 4.3*
Data are mean ± SE (n = 6-7).
*Significantly different from the control group at p < 0.05.Serum cholesterol in rats fed the squid diet was signifi-
cantly lower than in those fed the control diet (Tables 2
and 5). In Exp. 1, higher hepatic cholesterol in the squid
group was seen compared to that in the control group
(Table 2). This increased level of cholesterol in the liver
is not derived from hepatic cholesterol synthesis but,
rather, probably is due to the small amount of endogenous
cholesterol in squid homogenate because no difference of
hepatic cholesterol was found in Exp.2 in which choles-
terol levels in the diets were the same. In Table 7, fecal
excretion of neutral steroids (including cholesterol) was
not modified by the diets, suggesting that decreased chol-
esterol in blood may not be due to diminished absorption
of dietary cholesterol in the small intestine. On the other
hand, feeding the squid diet gave a significantly lower
gene expression of intestinal CD36 and NPC1L1, both
of which are necessary for intestinal cholesterol trafficking
(Figure 2). By contrast, fecal excretion of acidic steroids
(bile acids) was significantly higher in the squid group
accompanied with a non-significant decrease in mRNA
of IBABP (p =0.1) (Table 7 and Figure 2). Thus, hypo-
cholesterolemic action of squid is likely to be secondary
to enhanced fecal excretion of bile acid rather than an
inhibition of cholesterol absorption in the small intes-
tine. Our results are not in agreement with those by
Childs et al. showing that some shellfish exerted lower
cholesterol absorption in humans [13]. Different source
of shellfish proteins and species difference may explain
the contradiction. Gene expression of CYP7A1 tended
to be higher without a significant difference (p =0.08,
Figure 1). Decreased absorption of bile acids might have
induced hepatic mRNA for CYP7A1, probably stimulat-
ing conversion of cholesterol to bile acid. Though gene
expression of CYP7A1 is known to be regulated by FXR
[29], hepatic FXR gene expression was not modulated
by squid homogenate (Figure 1). It has been reported
that bile acids in the small intestine activate intestinal
FXR, and in turn FXR stimulates FGF15/19 production
Figure 1 Effects of the diets on hepatic mRNA expression of lipid metabolism-related genes. Data are mean ± SE (n = 6-7). □: the control
diet, ■: the squid diet. *: Significantly different from the control group at p <0.05.
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repress CYP7A1 expression [30]. Since bile acids were
excreted into feces more by the squid diet, it is likely
that decreased absorption of bile acids in intestinal cells
might have repressed ileum FXR gene expression (Figure 2),
consequently enhancing bile acid synthesis in the liver
through decreased FGF15. Thus, although FGF15 was
not measured in the present study, FXR/FGF15 intestine-
liver pathway may be at least in part responsible for
hepatic increased level of CYP7A1. Further studies are
needed to prove our hypothesis as, most likely due to a
large standard error, no clear difference of gene expres-
sion of CYP7A1 in the liver and FXR and IBABP in the
small intestine was observed. Treatment with chole-
styramine, bile acid sequestrant, has been reported to
lower serum FGF19, but simultaneously elevate blood bile
acid levels in humans probably via increased synthesis of
bile acid [31]. However, bile acid sequestrant concomitantly
increased plasma triglyceride in some studies [32,33].
Similar to cholestyramine, squid homogenate stimulatedFigure 2 Effects of the diets on intestinal mRNA expression of lipid m
diet, ■: the squid diet. *: Significantly different from the control group at pfecal excretion of bile acid, but indeed decreased serum
triglyceride level in our study (Tables 2 and 5). Reasons
for the discrepancy on serum triglyceride between squid
homogenate and cholestyramine remain unclear at
present. Since Kim et al. showed that the small intestine
plays a much more prominent role in repressing CYP7A1
expression than the liver [34], further detailed studies on
an intestinal role in bile acid and lipid metabolism in
squid-fed rats are warranted.
There is the discrepancy of effects of squid on hepatic
lipid levels between our study and the previous study
[15]. Tanaka et al. used 0.5% cholesterol- and defatted
squid-supplemented diets and higher level of squid pro-
tein (~15%), and showed that in addition to decreased
lipids in blood, hepatic levels of cholesterol and trigly-
ceride were also lower by feeding squid [15]. This
discrepancy on hepatic lipid might have been largely at-
tributed to the difference of dietary composition, but
effects of defatting, which may remove factors affecting
lipid metabolism, cannot be ruled out.etabolism-related genes. Data are mean ± SE (n = 6-7). □: the control
<0.05.
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soybean are capable of binding to bile acids in the small
intestine [18,19,21]; vegetable proteins and their peptides
bind to cholesterol and/or bile acids in the small intes-
tine and stimulate fecal excretion of steroids, resulting in
lowered blood and liver cholesterol. Although hypolipid-
emic effects of vegetable proteins and peptides were not
constant [19-21], some peptides from vegetable proteins
appears to increase mRNA of CYP7A1, LPL and low
density lipoprotein receptor (LDLR), indicating the pos-
sibility that peptides may lower cholesterol by enhanced
bile acid synthesis through CYP7A1, and decrease trigly-
ceride by enhanced clearance through LPL and LDLR
[26-28]. In addition, since, as mentioned above, a lower
amount of homogenate was required to induce hypolip-
idemic action in the current study than in the previous
study [15], it is worth finding peptides responsible for
hypolipidemic action from squid to develop novel func-
tional foods. Studies are currently under way in our
laboratory to pinpoint peptides.Table 8 Nutrient composition in the diets *(g)
Experiment 1 Experiment 2
Control Squid Control Squid
Casein* 20.0 15.0 20.0 15.0
Squid homogenate** - 8.143 - 8.143
α-Com starch 13.2 13.2 13.2 13.2
Soybean oil 7.0 7.0 7.0 7.0Conclusion
The present study shows that regardless of the pres-
ence or absence of dietary cholesterol in the diets,
squid homogenate is capable of lowering serum lipids
in rats. Newly-developed squid homogenate favorably
alters lipid metabolism by changes in hepatic fatty acid
synthesis in addition to lipid handling in the small
intestine. Decreased secretion of lipids as VLDL from
the liver may also be involved in serum lipid levels as
suggested by down-regulated gene expression of MTP.
The squid diet supplemented with or without cho-
lesterol significantly lowered serum cholesterol, but
serum triglyceride was affected to a greater extent.
These results could provide new dietary strategies to
maintain healthy levels of serum cholesterol and trigly-
ceride. Further studies are definitely merited to figure
out the detailed mechanism responsible for hypolipid-
emic action of squid and responsible peptide fraction.Sucrose 10.0 10.0 10.0 10.0
Cellulose 5.0 5.0 5.0 5.0
Mineral mix AIN-93G 3.5 3.5 3.5 3.5
Vitamin mix AIN-93G 1.0 1.0 1.0 1.0
Tert-Butylhydroquinone 0.0014 0.0014 0.0014 0.0014
Choline bitartrate 0.25 0.25 0.25 0.25
L-Cystine 0.30 0.30 0.30 0.30
Cholesterol - 0.0529*** 0.10 0.10****
β-Com starch 39.75 36.61 39.65 36.56
Total (g) 100.0 100.0 100.0 100.0
*Purchased from Wako Pure Chemical Industries. (Osaka, Japan).
**Squid homogenate was equivalent to 5 g of protein.
***Endogenous cholesterol in squid.
****Endogenous plus dietary cholesterol.Methods
Animal experiments
Four week-old male Sprague–Dawley rats were pur-
chased from Japan SLC (Shizuoka, Japan), housed indi-
vidually in stainless-steel cages under a controlled
atmosphere (temperature, 22 ± 1°C, humidity, 55 ± 5%,
light cycle, 0800–20:00), fed a commercial pellet diet
(CE-2, Clea Japan, Tokyo) for a week, and then given
the experimental diets. Animal studies were carried
out under the Guidelines for Animal Experiments of
University of Nagasaki (Nagasaki, Japan), and Law
no.105 and Notification no. 6 of the Government of
Japan.Preparation of homogenated squid muscle with sodium
citrate
Approximately 310 g in body weight of Japanese com-
mon squid (Todarodes pacificus) with 25 cm in mantle
length was caught off the coast of Nagasaki prefecture,
Japan. The squid were gutted and skinned immediately.
Mantle muscle was minced and extruded with a diam-
eter of 1.2 mm. The minced mantle muscle was treated
with sodium citrate at the concentration of 2% (w/w)
and blended as described elsewhere [16]. Then, the
minced squid muscle was lyophilized and powdered
before use. The electrophoretic pattern of sodium citrate-
treated squid proteins was well characterized in compari-
son with non-treated squid homogenate [25]. The level of
protein, carbohydrate, fat, mineral, cholesterol, and water
in squid homogenate was 61.4%, 0.1%, 2.2%, 18.3%, 0.65%
and 17.4%, respectively, as dry matter.
Experimental diet
Experiment 1
To see if squid homogenate has potential in reducing
blood lipids in comparison with a casein-based AIN-93G
cholesterol-free diet, rats were assigned to 2 groups of 6
animals. The dietary composition is described in Table 8.
The proportion of energy derived from protein, fat and
carbohydrate was 20%, 16% and 64%, respectively, in the
control diet, and 21%, 17% and 62%, respectively, in the
squid diet. Animals were fed the diets for 4 weeks and
sacrificed after 6 hours fasting. Blood was withdrawn
and was centrifuged at 1500 g for 20 min after clotting.
Nagata et al. Lipids in Health and Disease 2014, 13:165 Page 8 of 10
http://www.lipidworld.com/content/13/1/165The liver and adipose tissue were excised, frozen imme-
diately in liquid nitrogen and stored at −80°C before
analysis. Serum and hepatic lipid concentrations were
measured as described below. Activity of hepatic en-
zymes involved in lipid metabolism was also determined.Experiment 2
To see if squid homogenate has potential in reducing
blood lipid in the presence of dietary cholesterol, rats
were given one of two diets prepared as described in
Exp. 1 except that cholesterol was added at the level of
0.1% and 0.047% to the control diet and the squid diet,
respectively, to provide the same amount of dietary
cholesterol. Animals fed the diets for 4 weeks were
sacrificed after 6 hours fasting. In addition to the liver
and adipose tissue, the entire small intestine was col-
lected, flushed with ice-cold saline, divided into two
segments designated as jejunum and ileum, respect-
ively, and stored in −80°C before use. Serum and
hepatic lipid concentrations and activity of enzymes
involved in lipid metabolism were also determined as
in Exp. 1. Gene expression of proteins responsible for
lipid metabolism in the liver and the small intestine
was determined by quantitative real-time PCR, as de-
scribed below. Feces were collected for two days before
sacrifice, and fecal excretion of fatty acid and steroids
was measured.Serum and tissue biochemical analyses
Serum lipids were assayed enzymatically using com-
mercial kits (Cholesterol E-test, Triglyceride E-test,
Phospholipid C-Test, Wako Pure Chemical Industries,
Osaka, Japan). Liver lipids were extracted by the
method of Folch et al. [35], and then the concentra-
tions of cholesterol, phospholipid, and triglyceride













SREBP-1c 5′GACCGACATCGAAGGTGAAGTC-3Analyses of enzyme activity and gene expression of lipid
metabolism-related proteins
The liver was excised, frozen immediately in liquid nitro-
gen and stored at −80°C before use. A small aliquot of the
excised liver was homogenized in 6 volumes of 0.25 M
sucrose solution containing 10 mM Tris–HCl and 1 mM
EDTA (pH7.4). After sedimentation of the nuclei fraction,
the supernatant was centrifuged to sediment mitochondria
at 12,000 g for 10 min. Then, the supernatant was again
centrifuged at 100,000 g for 60 min to precipitate micro-
somes, and the remaining supernatant was used as cytosol
fraction. The mitochondrial and microsomal pellets were
resuspended in the same 0.25 M sucrose solution. Activ-
ities of cytosol fatty acid synthase (FAS) [36] and glucose-
6-phosphate dehydrogenase (G6PDH) [37] and malic
enzyme (ME) [38] were measured. Microsomal phospha-
tidate phosphohydrolase (PAP) [39] and mitochondrial
carnitine palmitoyltransferase (CPT) [40] were also deter-
mined. Interscapular brown adipose tissue was collected
and homogenized as described above, and mitochondrial
CPT activity was measured. Protein was assayed by the
method of Lowry et al. [41].
Total RNA was extracted from the small intestine and
the liver using RNA extraction reagent (RNAiso Plus,
Takara Bio, Shiga, Japan) according to the manufacturer’s
instructions. Total RNA (1 μg) was reverse-transcribed to
synthesize cDNA with reverse-transcription kit (Prime-
Script ®RT Master Mix, Takara Bio, Shiga, Japan). Real
time PCR was performed on a 7300 Real-Time PCR sys-
tem (Applied Biosystems, CA, USA) using the manufac-
turer’s standard protocol. The PCR reaction mixture
was prepared using THUNDERBIRD SYBR qPCR Mix
(TOYOBO, Osaka, Japan). The messenger RNA (mRNA)
levels, measured relative to 36B4 mRNA levels used
as an internal control, were determined using the
2 − ΔΔCt method. The primers used in this study are
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In Exp 2, feces were collected for 2 days before sacri-
fice, lyophilized, and ground. A small aliquot of feces
was extracted by the method of Ikeda et al. [42] and mea-
sured for lipid excretion with gas chromatography. Neutral
and acidic steroids were measured by 5α-cholestane and
23-nordeoxycholic acid as internal standards, respectively.
An excretion of fatty acid into feces was determined by a
titration method [43].
Statistical analysis
Statistical analysis was done by Independent t-test using
IBM SPSS Statistics 20.0. P <0.05 was considered significant.
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